enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Down 60.0% in October

enGene Holdings Inc. (NASDAQ:ENGNW) was the recipient of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 1,000 shares, a decrease of 60.0% from the October 15th total of 2,500 shares. Based on an average daily trading volume, of 3,300 shares, the short-interest ratio is currently 0.3 days.

enGene Stock Performance

NASDAQ ENGNW traded up $0.06 on Friday, reaching $1.51. The company had a trading volume of 12,682 shares, compared to its average volume of 19,480. enGene has a fifty-two week low of $0.40 and a fifty-two week high of $6.50. The business has a 50 day moving average of $1.70 and a two-hundred day moving average of $1.79.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.